HCRN-GU23-651
A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
HCRN GU24-688
A Phase II, open-label, single-arm study of nEoadjuvant zanzalintinib (XL092) Plus nivoLumab in patients with locally advanced and/or surgically challenging clear cell Renal Cell Carcinoma with or without non-measurable metastasis (EXPLORE-RCC)
HCRN-GI23-621
A phase II study of pemigatinib plus durvalumab (MEDI4736) in previously treated advanced intrahepatic cholangiocarcinoma patients with FGFR-2 fusion or rearrangement
HCRN-GU22-595
EXACT: Randomized phase II trial of XL092 in combination with immunotherapy in patients who progress on Adjuvant therapy in Clear Cell RCC
HCRN-GI23-617
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors.
HCRN-GU22-598
Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder
HCRN-GU21-551
ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
HCRN-AML20-472
TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
HCRN-BRE17-141
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER2-Positive Breast Cancers
HCRN-BRE20-468
A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
HCRN-GI18-333
Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL)
HCRN-GU16-243
PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243
HCRN-GU21-517
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)
HCRN-GU22-587
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)
HCRN-LUN21-530
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)
HCRN-LUN21-534
DURABLE: Delayed or Upfront brain RAdiotherapy in treatment naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and rEarrangements
HCRN-LUN23-618
Phase II study of adagrasib + stereotactic radiosurgery (SRS) for patients with metastatic KRAS G12C-mutated NSCLC with untreated brain metastases
HCRN-LYM21-544
Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms
HCRN-LYM21-546
A phase II study of pembrolizumab and mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphomas
HCRN-LYM22-565
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
HCRN-MCC20-443
A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT Study)
TBCRC047
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
BTCRC-GI21-500
A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination with Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI21-500
BTCRC-GI22-588
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
BTCRC-HEM15-027
Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027
BTCRC-LUN18-153
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
BTCRC-LUN20-462
A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second Line Treatment for Small Cell Lung Cancer
